Infections explained by auto-Abs against type I IFN and OR as compared to the general population
| Infections . | % of cases with auto-Abs . | OR (95% confidence interval) . | |
|---|---|---|---|
| IFN-α and/or IFN-ω (100 pg/ml) . | IFN-α and IFN-ω (10 ng/ml) . | ||
| Critical COVID-19 pneumonia | 14% | 13 (8–21) | 67 (4–1,109) |
| Fatal COVID-19 under 70 years old | 21% | 17.0 (11.7–24.8) | 156.5 (57.8–423.4) |
| Fatal COVID-19 above 70 years old | 15% | 5.8 (4.5–7.4) | 12.9 (8.4–19.9) |
| Pediatric COVID-19 pneumonia | 10% | 5.3 (2.8–9.6) | 112 (12–14,991) |
| Breakthrough hypoxemic COVID-19 pneumonia | 24% | - | - |
| Severe flu before 70 years old | 6% | 5.7 (3.0–11.1) | 139.9 (42.3–462.5) |
| Avian flu | 100%a | - | - |
| WNV neuroinvasive disease (study 1) | 39% | 21.1 (16.4–27.1) | 138.4 (93.3–205.4) |
| Under 65 years old | 22% | 24.4 (14.4–40.4) | 702 (266–2,149) |
| Above 65 years old | 47% | 24.5 (18.0–33.4) | 85.8 (56.8–131.2) |
| WNV neuroinvasive disease (study 2) | 38% | 16.8 (12.0–23.3) | 101.3 (63.2–162.3) |
| Under 65 years old | 23% | 26.6 (17.4–40.7) | 602 (224.2–1,616.2) |
| Above 65 years old | 44% | 22.3 (17.1–29.1) | 84.6 (57.6–124.2) |
| Severe TBEV encephalitis | 10% | 4.9 (1.5–15.9) | 20.8 (4.5–97.4) |
| Severe POWV encephalitis | 100%a | - | - |
| Severe USUV infection | 67% | - | - |
| Severe RRV disease | 4%b | - | - |
| Yellow fever virus vaccine disease | 38% | - | - |
| Severe reaction to chikungunya vaccine | 60% | - | - |
| HSV-triggered fulminant viral hepatitis | 38% | 29.7 (11.3–77.9) | 1,873.9 (444.4–7,901.8) |
| Infections . | % of cases with auto-Abs . | OR (95% confidence interval) . | |
|---|---|---|---|
| IFN-α and/or IFN-ω (100 pg/ml) . | IFN-α and IFN-ω (10 ng/ml) . | ||
| Critical COVID-19 pneumonia | 14% | 13 (8–21) | 67 (4–1,109) |
| Fatal COVID-19 under 70 years old | 21% | 17.0 (11.7–24.8) | 156.5 (57.8–423.4) |
| Fatal COVID-19 above 70 years old | 15% | 5.8 (4.5–7.4) | 12.9 (8.4–19.9) |
| Pediatric COVID-19 pneumonia | 10% | 5.3 (2.8–9.6) | 112 (12–14,991) |
| Breakthrough hypoxemic COVID-19 pneumonia | 24% | - | - |
| Severe flu before 70 years old | 6% | 5.7 (3.0–11.1) | 139.9 (42.3–462.5) |
| Avian flu | 100%a | - | - |
| WNV neuroinvasive disease (study 1) | 39% | 21.1 (16.4–27.1) | 138.4 (93.3–205.4) |
| Under 65 years old | 22% | 24.4 (14.4–40.4) | 702 (266–2,149) |
| Above 65 years old | 47% | 24.5 (18.0–33.4) | 85.8 (56.8–131.2) |
| WNV neuroinvasive disease (study 2) | 38% | 16.8 (12.0–23.3) | 101.3 (63.2–162.3) |
| Under 65 years old | 23% | 26.6 (17.4–40.7) | 602 (224.2–1,616.2) |
| Above 65 years old | 44% | 22.3 (17.1–29.1) | 84.6 (57.6–124.2) |
| Severe TBEV encephalitis | 10% | 4.9 (1.5–15.9) | 20.8 (4.5–97.4) |
| Severe POWV encephalitis | 100%a | - | - |
| Severe USUV infection | 67% | - | - |
| Severe RRV disease | 4%b | - | - |
| Yellow fever virus vaccine disease | 38% | - | - |
| Severe reaction to chikungunya vaccine | 60% | - | - |
| HSV-triggered fulminant viral hepatitis | 38% | 29.7 (11.3–77.9) | 1,873.9 (444.4–7,901.8) |